市場調查報告書

傳染性軟疣(MC)- 市場洞察,流行病學,預測 2028年

Molluscum Contagiosum (MC) - Market Insights, Epidemiology, and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 918181
出版日期 內容資訊 英文 129 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
傳染性軟疣(MC)- 市場洞察,流行病學,預測 2028年 Molluscum Contagiosum (MC) - Market Insights, Epidemiology, and Market Forecast - 2028
出版日期: 2019年12月01日內容資訊: 英文 129 Pages
簡介

主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的傳染性軟疣(MC)的2017年的患病數估算為1,216萬1,039人,同年的市場規模估算為21億8,343萬美元。

本報告提供主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的傳染性軟疣(MC)市場相關調查,疾病概要和現行的治療方法,新藥的簡介,主要7個國家的市場趨勢,流行病學的預測,市場規模,患病數的變化與預測,未滿足需求,市場成長要素及障礙等資訊總括性彙整。

目錄

第1章 重要洞察

第2章 傳染性軟疣(MC)市場概要

  • 傳染性軟疣(MC)的分佈(實數值)
  • 傳染性軟疣(MC)的分佈(預測值)

第3章 鑰匙摘要

第4章 流行病學與調查手法

第5章 疾病背景:傳染性軟疣(MC)

  • 簡介
  • 病因
  • 症狀
  • 原因
  • 診斷
  • 鑑別診斷

第6章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的傳染性軟疣(MC)的總患病數
  • 美國
    • 假設和理論性根據
    • 傳染性軟疣(MC)的總患病數
    • 傳染性軟疣(MC)的患病數:各年齡
    • 傳染性軟疣(MC)的患病數:性別
  • 歐盟5國
    • 德國
      • 假設和理論性根據
      • 傳染性軟疣(MC)的總患病數
      • 傳染性軟疣(MC)的患病數:各年齡
      • 傳染性軟疣(MC)的患病數:性別
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本
    • 假設和理論性根據
    • 傳染性軟疣(MC)的總患病數
    • 傳染性軟疣(MC)的患病數:各年齡
    • 傳染性軟疣(MC)的患病數:性別

第7章 現行治療

第8章 未滿足需求

第8章 案例研究

第9章 新藥

  • VP-102/Cantharidin:Verrica Pharmaceuticals
    • 產品概要
    • 產品開發趨勢
    • 臨床趨勢
    • 安全性和有效性
    • 產品簡介
  • SB206: Novan/Ligand Pharmaceuticals
  • VBP-245: Veloce Biopharma

第10章 市場規模

  • 主要調查結果
  • 主要7個國家的整體市場規模
  • 主要7個國家的市場規模:各治療藥物

第11章 美國市場預測

  • 整體市場規模
  • 市場規模:各治療藥物

第12章 歐盟5國市場預測

  • 德國
    • 整體市場規模
    • 市場規模:各治療藥物
  • 法國
  • 義大利
  • 西班牙
  • 英國

第13章 日本市場預測

  • 日本
    • 整體市場規模
    • 市場規模:各治療藥物

第14章 市場成長要素

第15章 市場障礙

第16章 關鍵意見領袖的意見

第17章 附錄

第18章 DelveInsight的服務內容

第19章 免責聲明

第20章 關於DelveInsight

目錄
Product Code: DIMI0747

DelveInsight's 'Molluscum Contagiosum (MC)- Market Insights, Epidemiology, and Market Forecast-2028' report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Molluscum Contagiosum in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Molluscum Contagiosum from 2017 to 2028 segmented by seven major markets.

Molluscum Contagiosum is a common superficial skin infection caused by the poxvirus (Molluscum Contagiosum virus), it is one of the 50 most frequent diseases worldwide. The virus is transmitted mainly by direct contact with infected skin, which can be sexual, nonsexual, or autoinoculation. It is common in children and generally presents with asymptomatic lesions; however, it can present with pruritus, erythema, and on some occasions, bacterial super infections with inflammation and pain.

MC is characterized by painless white or skin-colored papular skin-lesions that are generally 2-5 mm in size, though early lesions can be smaller.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Molluscum Contagiosum - Disease Understanding and Treatment Algorithm

In Molluscum Contagiosum the patients typically have 1-20 molluscum lesions, although even healthy patients may have a hundred or more lesions. In normal hosts, MC is benign natured, limited to the skin, but lesions can take as long as 6-12 months to resolve. Immunocompromised patients can develop very large (>15 mm) and numerous lesions, and bacterial super infections.

The diagnosis is based on clinical findings. A useful clinical tool is a dermoscopy. If the diagnostic doubt persists, confocal microscopy or skin biopsy could be performed. Treatment is not necessary for most cases of MC as lesions are generally self-limiting and resolve without scarring. The need for active treatment for MC is controversial; as it is a frequent reason for consultation in pediatric dermatology, and given its self-limited nature, the decision to treat or not becomes complex and varied up on a case-by-case basis. Clinical inflammation has been observed as preliminary step for spontaneous regression of some MC lesions

Molluscum Contagiosum Epidemiology

The Molluscum Contagiosum epidemiology division provides insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalence of Molluscum Contagiosum in 7MM, Gender-Specific Prevalence of Molluscum Contagiosum in 7MM, Age-Specific Prevalence of Molluscum Contagiosum,), scenario of Molluscum Contagiosum in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total prevalent cases of Molluscum Contagiosum in the 7MM was found to be 12,161,039 in 2017. The prevalence of Molluscum Contagiosum in the 7MM is expected to increase during the study period of 2017-2028.

Molluscum Contagiosum Drug Chapters

This segment of the Molluscum Contagiosum report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The current market of the Molluscum Contagiosum is centered with the destruction of lesions by cryotherapy, curettage, laser, salicylic acid. Alternatively, immune-modulating therapies, such as topical imiquimod, cimetidine, chemical methods such as trichloroacetic acid, cantharidin, tretinoin, tazarotene, podophyllotoxin are in use. Along with this, combination therapies have been used in attempts to speed up the healing of MC lesions.

Cryotherapy and curettage are the top choices as the treatment for all health care providers as it has shown effective results. Curettage generally requires a topical anesthetic, which is probably the most effective technique that requires skill and patient collaboration, which is often lacking. Moreover, these techniques can cause scarring, hypo or hyperpigmentation, and can be painful, especially for children.

Salicylic Acid is also used to treat MC, advantages of these acids include convenience, reasonable cost, minimal discomfort, and reasonable effectiveness. Disadvantages include the length of time before results are seen and complex curetting.

Along with this, Immunotherapeutic methods are used which are based on the stimulation of a cellular and/or humoral immune response that can eliminate the viral infection

Combination therapies, including two or more modes of therapy (destructive, cytotoxic, antivirals, or immune modulators) may be used to increase the response rate, as well as the speed of resolution.

Several companies are working robustly on many new therapies, such as as VP-102 (Verrica Pharmaceuticals), SB206 (Novan/Ligand Pharmaceuticals), VBP-245 (Veloce Biopharma) and others. These all are anticipated to enter the Molluscum Contagiosum market by 2028.

Molluscum Contagiosum Market Outlook

The Molluscum Contagiosum market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

According to DelveInsight, the market of Molluscum Contagiosum in 7MM was found to be approximately USD 2,183.43 Million in 2017.

Molluscum Contagiosum market size in the United States accounted for approx. 59% of the total market in 2017. The EU5 led the market in 2017, followed by the US and Japan respectively. Due to the high prevalence of this disease in the region, the Molluscum Contagiosum treatment market in the EU5 is expected to dominate the market during the forecast period (2019-2028).

Molluscum Contagiosum Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

Currently, the market of molluscum Contagiosum depend on off-label therapies such as the cryotherapy, curettage, laser, salicylic acid. Immune-modulating therapies, such as topical imiquimod, cimetidine, chemical methods such as trichloroacetic acid and others.

The therapies are in the stage of development being developing by VP-102 (Verrica Pharmaceuticals), SB206 (Novan/Ligand Pharmaceuticals), VBP-245 (Veloce Biopharma) for patients with Molluscum Contagiosum.

Molluscum Contagiosum Report Insights

  • Patient Population of Molluscum Contagiosum
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Molluscum Contagiosum Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Molluscum Contagiosum Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Molluscum Contagiosum market
  • Organize sales and marketing efforts by identifying the best opportunities for Molluscum Contagiosum market
  • To understand the future market competition in the Molluscum Contagiosum market

Table of Contents

1. Key Insights

2. Molluscum Contagiosum (MC): Market Overview at a Glance

  • 2.1. Total Market Share (%) Distribution of MC in 2017
  • 2.2. Total Market Share (%) Distribution of MC in 2028

3. Key Summary

4. Epidemiology and Market Methodology

5. Disease Overview: Molluscum Contagiosum (MC)

  • 5.1. Introduction
  • 5.2. Causes
  • 5.3. Symptoms
  • 5.4. Pathogenesis
  • 5.5. Diagnosis
  • 5.6. Differential Diagnosis

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. Total Prevalent cases of Molluscum Contagiosum in 7MM
  • 6.3. United States
    • 6.3.1. Assumptions and Rationale
    • 6.3.2. Total Prevalent cases of Molluscum Contagiosum in the US
    • 6.3.3. Age-Specific Prevalent cases of Molluscum Contagiosum in the US
    • 6.3.4. Gender-Specific cases of Molluscum Contagiosum in the US
  • 6.4. EU5
    • 6.4.1. Assumptions and Rationale
  • 6.5. Germany
    • 6.5.1. Total Prevalent cases of Molluscum Contagiosum in Germany
    • 6.5.2. Age-Specific Prevalent cases of Molluscum Contagiosum in Germany
    • 6.5.3. Gender-Specific cases of Molluscum Contagiosum in Germany
  • 6.6. France
    • 6.6.1. Total Prevalent cases of Molluscum Contagiosum in France
    • 6.6.2. Age-Specific Prevalent cases of Molluscum Contagiosum in France
    • 6.6.3. Gender-Specific cases of Molluscum Contagiosum in France
  • 6.7. Italy
    • 6.7.1. Total Prevalent cases of Molluscum Contagiosum in Italy
    • 6.7.2. Age-Specific Prevalent cases of Molluscum Contagiosum in Italy
    • 6.7.3. Gender-Specific cases of Molluscum Contagiosum in Italy
  • 6.8. Spain
    • 6.8.1. Total Prevalent cases of Molluscum Contagiosum in Spain
    • 6.8.2. Age-Specific Prevalent cases of Molluscum Contagiosum in Spain
    • 6.8.3. Gender-Specific cases of Molluscum Contagiosum in Spain
  • 6.9. United Kingdom (UK)
    • 6.9.1. Total Prevalent cases of Molluscum Contagiosum in the UK
    • 6.9.2. Age-Specific Prevalent cases of Molluscum Contagiosum in the UK
    • 6.9.3. Gender-Specific cases of Molluscum Contagiosum in the UK
  • 6.10. Japan
    • 6.10.1. Assumptions and Rationale
    • 6.10.2. Total Prevalent cases of Molluscum Contagiosum in Japan
    • 6.10.3. Age-Specific Prevalent cases of Molluscum Contagiosum in Japan
    • 6.10.4. Gender-Specific cases of Molluscum Contagiosum in Japan

7. Current Treatment

  • 7.1. Treatment Guidelines
  • 7.2. Approach to treat Molluscum Contagiosum in pediatric patient- Spain

8. Unmet Needs

9. Emerging Drugs

  • 9.1. Key Cross Competition Emerging Therapies
  • 9.2. VP-102/Cantharidin: Verrica Pharmaceuticals
    • 9.2.1. Drug Description
    • 9.2.2. Other Developmental Activities
    • 9.2.3. Clinical Development
    • 9.2.4. Safety and Efficacy
    • 9.2.5. Product Profile
  • 9.3. SB206: Novan/Ligand Pharmaceuticals
    • 9.3.1. Drug Description
    • 9.3.2. Other Developmental Activities
    • 9.3.3. Clinical Development
    • 9.3.4. Safety and Efficacy
    • 9.3.5. Product Profile
  • 9.4. VBP-245: Veloce Biopharma
    • 9.4.1. Drug Description
    • 9.4.2. Other Developmental Activities
    • 9.4.3. Clinical Development
    • 9.4.4. Safety and Efficacy
    • 9.4.5. Product Profile

10. Market Size

  • 10.1. Key Findings
  • 10.2. Total Market Size of MC in 7MM
  • 10.3. Total Market Size of MC by Therapies in 7MM

11. US: Market Outlook

  • 11.1. Total Market size of Molluscum Contagiosum in the US
  • 11.2. Market size of Molluscum Contagiosum by Therapies

12. EU-5: Market outlook

  • 12.1. Germany
    • 12.1.1. Total Market size of Molluscum Contagiosum in Germany
    • 12.1.2. Market size of Molluscum Contagiosum by Therapies
  • 12.2. France
    • 12.2.1. Total Market size of Molluscum Contagiosum in France
    • 12.2.2. Market size of Molluscum Contagiosum by Therapies
  • 12.3. Italy
    • 12.3.1. Total Market size of Molluscum Contagiosum in Italy
    • 12.3.2. Market size of Molluscum Contagiosum by Therapies
  • 12.4. Spain
    • 12.4.1. Total Market size of Molluscum Contagiosum in Spain
    • 12.4.2. Market size of Molluscum Contagiosum by Therapies
  • 12.5. United Kingdom
    • 12.5.1. Total Market size of Molluscum Contagiosum in the UK
    • 12.5.2. Market size of Molluscum Contagiosum by Therapies

13. Japan: Market Outlook

  • 13.1. Japan Market Size
    • 13.1.1. Total Market size of Molluscum Contagiosum in Japan
    • 13.1.2. Market size of Molluscum Contagiosum by Therapies

14. Market Drivers

15. Market Barriers

16. KOL Views - MC

17. Appendix

  • 17.1. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

List of Tables

  • Table 1: Defense mechanisms used by Molluscum contagiosum virus to avoid immunologic reactions
  • Table 2: Molluscum contagiosum differential diagnosis
  • Table 3: Total Prevalent cases of Molluscum Contagiosum in 7MM (2017-2028)
  • Table 4: Total Prevalent Cases of Molluscum Contagiosum in the US (2017-2028)
  • Table 5: Age-Specific Prevalent Cases of Molluscum Contagiosum in the US (2017-2028)
  • Table 6: Gender-Specific Prevalent Cases of Molluscum Contagiosum in the US (2017-2028)
  • Table 7: Total Prevalent Cases of Molluscum Contagiosum in Germany (2017-2028)
  • Table 8: Age-Specific Prevalent Cases of Molluscum Contagiosum in Germany (2017-2028)
  • Table 9: Gender-Specific Prevalent Cases of Molluscum Contagiosum in Germany (2017-2028)
  • Table 10: Total Prevalent Cases of Molluscum Contagiosum in France (2017-2028)
  • Table 11: Age-Specific Prevalent Cases of Molluscum Contagiosum in France (2017-2028)
  • Table 12: Gender-Specific Prevalent Cases of Molluscum Contagiosum in France (2017-2028)
  • Table 13: Total Prevalent Cases of Molluscum Contagiosum in Italy (2017-2028)
  • Table 14: Age-Specific Prevalent Cases of Molluscum Contagiosum in Italy (2017-2028)
  • Table 15: Gender-Specific Prevalent Cases of Molluscum Contagiosum in Italy (2017-2028)
  • Table 16: Total Prevalent Cases of Molluscum Contagiosum in Spain (2017-2028)
  • Table 17: Age-Specific Prevalent Cases of Molluscum Contagiosum in Spain (2017-2028)
  • Table 18: Gender-Specific Prevalent Cases of Molluscum Contagiosum in Spain (2017-2028)
  • Table 19: Total Prevalent Cases of Molluscum Contagiosum in the UK (2017-2028)
  • Table 20: Age-Specific Prevalent Cases of Molluscum Contagiosum in the UK (2017-2028)
  • Table 21: Gender-Specific Prevalent Cases of Molluscum Contagiosum in the UK (2017-2028)
  • Table 22: Total Prevalent Cases of Molluscum Contagiosum in Japan (2017-2028)
  • Table 23: Age-Specific Prevalent Cases of Molluscum Contagiosum in Japan (2017-2028)
  • Table 24: Gender-Specific Prevalent Cases of Molluscum Contagiosum in Japan (2017-2028)
  • Table 25: Methods of Destroying Warts
  • Table 26: Immune-modulating Methods of Wart Treatment
  • Table 27: Key cross competition
  • Table 28: VP-102, Clinical Trial Description, 2019
  • Table 29: SB206, Clinical Trial Description, 2019
  • Table 30: VBP-245, Clinical Trial Description, 2019
  • Table 31: Total Market Size of MC in 7MM in USD Million (2017-2028)
  • Table 32: Total Market Size of MC by Therapies in 7MM in USD Million (2017-2028)
  • Table 33: Total Market size of Molluscum Contagiosum in the US (2017-2028)
  • Table 34: Total Market Size of MC by Therapies in the US in USD Million (2017-2028)
  • Table 35: Total Market size of Molluscum Contagiosum in Germany (2017-2028)
  • Table 36: Total Market Size of MC by Therapies in Germany, in USD Million (2017-2028)
  • Table 37: Total Market size of Molluscum Contagiosum in Germany (2017-2028)
  • Table 38: Total Market Size of MC by Therapies in France, in USD Million (2017-2028)
  • Table 39: Total Market size of Molluscum Contagiosum in Italy (2017-2028)
  • Table 40: Total Market Size of MC by Therapies in Italy, in USD Million (2017-2028)
  • Table 41: Total Market size of Molluscum Contagiosum in Spain (2017-2028)
  • Table 42: Total Market Size of MC by Therapies in Spain, in USD Million (2017-2028)
  • Table 43: Total Market size of Molluscum Contagiosum in the UK (2017-2028)
  • Table 44: Total Market Size of MC by Therapies in the UK, in USD Million (2017-2028)
  • Table 45: Total Market size of Molluscum Contagiosum in Japan (2017-2028)
  • Table 46:Total Market Size of MC by Therapies in Japan in USD Million (2017-2028)

List of Figures

  • Figure 1: Epidemiology and Market Methodology
  • Figure 2: Causes of Molluscum contagiosum
  • Figure 3: Signs and symptoms of Molluscum contagiosum include bumps on the skin
  • Figure 4: Dermatoscopic findings of MC
  • Figure 5: Total Prevalent cases of Molluscum Contagiosum in 7MM (2017-2028)
  • Figure 6: Total Diagnosed Prevalent Cases of Molluscum Contagiosum in the US (2017-2028)
  • Figure 7: Age-Specific Prevalent Cases of Molluscum Contagiosum in the US (2017-2028)
  • Figure 8: Gender-Specific Cases of Molluscum Contagiosum in the US (2017-2028)
  • Figure 9: Total Prevalent Cases of Molluscum Contagiosum in Germany (2017-2028)
  • Figure 10: Age-Specific Prevalent Cases of Molluscum Contagiosum in Germany (2017-2028)
  • Figure 11: Gender-Specific Cases of Molluscum Contagiosum in Germany (2017-2028)
  • Figure 12: Total Prevalent Cases of Molluscum Contagiosum in France (2017-2028)
  • Figure 13: Age-Specific Prevalent Cases of Molluscum Contagiosum in France (2017-2028)
  • Figure 14: Gender-Specific Cases of Molluscum Contagiosum in France (2017-2028)
  • Figure 15: Total Prevalent Cases of Molluscum Contagiosum in Italy (2017-2028)
  • Figure 16: Age-Specific Prevalent Cases of Molluscum Contagiosum in Italy (2017-2028)
  • Figure 17: Gender-Specific Cases of Molluscum Contagiosum in Italy (2017-2028)
  • Figure 18: Total Prevalent Cases of Molluscum Contagiosum in Spain (2017-2028)
  • Figure 19: Age-Specific Prevalent Cases of Molluscum Contagiosum in Spain (2017-2028)
  • Figure 20: Gender-Specific Cases of Molluscum Contagiosum in Spain (2017-2028)
  • Figure 21: Total Prevalent Cases of Molluscum Contagiosum in the UK (2017-2028)
  • Figure 22: Age-Specific Prevalent Cases of Molluscum Contagiosum in the UK (2017-2028)
  • Figure 23: Gender-Specific Cases of Molluscum Contagiosum in the UK (2017-2028)
  • Figure 24: Total Prevalent Cases of Molluscum Contagiosum in Japan (2017-2028)
  • Figure 25: Age-Specific Prevalent Cases of Molluscum Contagiosum in Japan (2017-2028)
  • Figure 26: Gender-Specific Cases of Molluscum Contagiosum in Japan (2017-2028)
  • Figure 27: Unmet Needs
  • Figure 28: Targets for improved dermatological care
  • Figure 29: Total Market Size of MC in 7MM in USD Million (2017-2028)
  • Figure 30: Total Market Size of MC by Therapies in 7MM in USD Million (2017-2028)
  • Figure 31: Market size of Molluscum Contagiosum in the US (2017-2028)
  • Figure 32: Market Size of Molluscum Contagiosum by Therapies in USD Million (2017-2028)
  • Figure 33: Market size of Molluscum Contagiosum in Germany(2017-2028)
  • Figure 34: Market Size of Molluscum Contagiosum by Therapies in USD Million (2017-2028)
  • Figure 35: Market size of Molluscum Contagiosum in France (2017-2028)
  • Figure 36: Market Size of Molluscum Contagiosum by Therapies in USD Million (2017-2028)
  • Figure 37: Market size of Molluscum Contagiosum in Italy (2017-2028)
  • Figure 38: Market Size of Molluscum Contagiosum by Therapies in USD Million (2017-2028)
  • Figure 39: Market size of Molluscum Contagiosum in Spain (2017-2028)
  • Figure 40: Market Size of Molluscum Contagiosum by Therapies in USD Million (2017-2028)
  • Figure 41: Market size of Molluscum Contagiosum in the UK (2017-2028)
  • Figure 42: Market Size of Molluscum Contagiosum by Therapies in USD Million (2017-2028)
  • Figure 43: Market size of Molluscum Contagiosum in Japan (2017-2028)
  • Figure 44: Market Size of Molluscum Contagiosum by Therapies in USD Million (2017-2028)
  • Figure 45:Market Drivers
  • Figure 46: Market barriers
Back to Top